连续性体外清除治疗二甲双胍相关性与二甲双胍诱导性乳酸酸中毒的系统评价
该系统评价检索EMBASE和MEDLINE至2021年11月30日,纳入83篇报告(75篇病例报告、4篇病例系列、4篇描述性回顾性综述),均为低质量证据。二甲双胍毒性接受连续性体外治疗患者总生存率85.8%,二甲双胍诱导性乳酸酸中毒与相关性乳酸酸中毒生存率分别为75.0%和87.4%。二甲双胍峰浓度平均70.5 mg/L、中位41.9 mg/L,体外清除率平均39.0 mL/min、中位42.1 mL/min(范围9.0-58.7 mL/min),消除半衰期平均27.5 h、中位23.0 h(范围7-74 h)。峰浓度与半衰期在较低浓度时无有意义关系,极高浓度(>200 mg/L)时半衰期有短于20 h的趋势;最大乳酸浓度及最低pH与生存率均无相关关系。作者认为因发表偏倚结果需谨慎解读,可作为未来研究的假设生成。
要点
- 二甲双胍毒性接受连续性体外治疗患者总生存率85.8%(n=83篇报告)。
- 二甲双胍诱导性乳酸酸中毒生存率75.0%,二甲双胍相关性乳酸酸中毒生存率87.4%。
- 体外清除率平均39.0 mL/min、中位42.1 mL/min(范围9.0-58.7 mL/min)。
- 消除半衰期平均27.5 h、中位23.0 h(范围7-74 h);峰浓度>200 mg/L时半衰期有短于20 h趋势。
- 最大乳酸浓度及最低pH与生存率均无相关关系;数据不足以评估清除率与生存率的关系。
适用人群与场景
- 二甲双胍中毒伴乳酸酸中毒、接受连续性体外清除治疗的患者,包括急性过量后中毒及慢性使用背景下发生急性肾损伤等系统性打击后中毒。
研究设计与关键结果
- 系统评价纳入83篇报告:75篇病例报告、4篇病例系列、4篇描述性回顾性综述,均为低质量证据。
- 接受连续性体外治疗的患者总生存率85.8%;二甲双胍诱导性乳酸酸中毒生存率75.0%,二甲双胍相关性乳酸酸中毒生存率87.4%。
- 二甲双胍峰浓度总体平均70.5 mg/L、中位41.9 mg/L;体外清除率平均39.0 mL/min、中位42.1 mL/min(范围9.0-58.7 mL/min)。
- 消除半衰期平均27.5 h、中位23.0 h(范围7-74 h);较低浓度时峰浓度与连续性体外治疗半衰期无有意义关系,极高浓度(>200 mg/L)时半衰期有短于20 h的趋势。
- 数据不足以可靠评估体外清除率与总生存率的关系;最大乳酸浓度与生存率、最低pH与生存率在两类二甲双胍毒性中均无相关关系。
- 仅两处发现既往发表的毒代动力学计算有误。
证据类型、等级与局限
- 证据类型:系统评价,纳入病例报告、病例系列和描述性回顾性综述,均为低质量证据。
- 原文提及血液透析目前为首选体外治疗方式(Grade 1D证据),但部分患者血流动力学不稳定难以耐受。
- 连续性肾脏替代治疗被视为血液透析不可用时的替代选择。
- 局限:因发表偏倚,结果需谨慎解读,仅作为未来研究的假设生成;需前瞻性研究以生存为主要终点,明确连续性治疗在二甲双胍中毒中是否非劣于间歇性血液透析。
对床旁实践的改变
- 对于血流动力学不稳定、无法耐受血液透析的二甲双胍中毒伴乳酸酸中毒患者,连续性肾脏替代治疗是可考虑的替代方式(原文基于血液透析Grade 1D证据及替代背景)。
- 二甲双胍诱导性乳酸酸中毒患者生存率(75.0%)低于相关性乳酸酸中毒(87.4%),提示临床需更积极评估此类患者。
- 最大乳酸浓度和最低pH不宜单独用于判断生存预后(原文报告二者与生存率无相关关系)。
指南或共识出处
- Clin Toxicol (Phila) 系统评价:Continuous extracorporeal clearance in metformin-associated lactic acidosis and metformin-induced lactic acidosis: a systematic review,检索至2021年11月30日。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Metformin poisoning with lactic acidosis is an uncommon yet clinically serious condition related to the inhibition of normal aerobic metabolism. Toxicity may occur after an acute overdose although it is much more common after a systemic insult, such as acute kidney injury, in the setting of chronic use. Hemodialysis is currently the preferred extracorporeal treatment modality (Grade 1D evidence) although some patients may be too hemodynamically unstable to tolerate it. Continuous renal replacement therapy is considered an alternative if hemodialysis is unavailable but an evaluation of survival amongst this specific treatment class is lacking.
OBJECTIVES: To assess overall survival and provide an updated review of the toxicokinetic elimination parameters of patients receiving continuous renal replacement therapy for metformin poisoning.
METHODS: A comprehensive search was performed using the EMBASE and MEDLINE libraries from inception until November 30, 2021. Data was extracted and findings were summarized. Toxicokinetic parameters were analyzed and confirmed for accuracy when data permitted.
RESULTS: Eighty-three reports met inclusion criteria. These consisted of only low-quality evidence including 75 case reports, four case series, and four descriptive retrospective reviews. Overall survival among patients suffering from metformin toxicity who received continuous extracorporeal treatment was 85.8%. When stratified between metformin-induced lactic acidosis and metformin-associated lactic acidosis, survival was 75.0% and 87.4%, respectively. Available continuous renal replacement therapy toxicokinetic parameters were quite heterogeneous. Errors in previously published toxicokinetic calculations were noted in only two instances. The overall average and median peak metformin concentrations were 70.5 mg/L and 41.9 mg/L, respectively. The average and median extracorporeal clearance rates were 39.0 mL/min and 42.1 mL/min (range 9.0-58.7 mL/min). The average and median elimination half-life parameters were 27.5 h and median 23.0 h. Elimination half-life ranged from seven to 74 h. There was no meaningful relationship between peak metformin concentration and continuous extracorporeal treatment half-life at lower concentrations, though at very high concentrations (over 200 mg/L), there was a trend towards a half-life below 20 h. There is insufficient data to robustly evaluate overall survival in relation to the extracorporeal clearance rate. Finally, there was no relevant relationship between maximal lactate concentration and survival, nor nadir pH and survival, for patients with either type of metformin toxicity.
CONCLUSIONS: This retrospective systematic analysis of published cases treating metformin related lactic acidosis with continuous renal replacement therapy notes an overall slightly greater survival percentage compared to previous publications of individuals requiring any modality of renal replacement therapy. Because of publication bias, these results should be interpreted with caution and serve as hypothesis generating for future research. Prospective study focusing on the most clinically meaningful endpoint - survival - will help elucidate if continuous modalities are non-inferior to intermittent hemodialysis in metformin toxicity.
参考来源
- Correia MS, Horowitz BZ. Continuous extracorporeal clearance in metformin-associated lactic acidosis and metformin-induced lactic acidosis: a systematic review. Clin Toxicol (Phila). 2022. PMID: 36239608. doi:10.1080/15563650.2022.2127363
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。